Full-Time

Vice President Specialty Operations

Option Care Health

Option Care Health

1,001-5,000 employees

Largest independent home infusion therapy provider

Compensation Overview

$207.2k - $345.4k/yr

Bannockburn, IL, USA

In Person

Bachelor's, Master's, MBA, PharmD

Category
Medical, Clinical & Veterinary (1)
Required Skills
Six Sigma
Process Engineering
Machine Learning
Risk Management
Care Coordination
Data Analysis

Get referred to Option Care Health

See people who can refer or advise you

Requirements
  • 15+ years of progressive leadership experience in specialty pharmacy, healthcare operations, specialty therapeutics, infusion services, or related sectors.
  • Significant executive leadership experience overseeing national, multi-site specialty pharmacy operations.
  • Extensive experience leading specialty pharmacy revenue cycle management, reimbursement, patient access, and buy-and-bill operations.
  • Demonstrated success managing large-scale national organizations with 1,000+ team members across multiple geographies and functions.
  • Proven ability to lead enterprise transformation initiatives involving digital technologies, automation, analytics, and artificial intelligence.
  • Strong history of delivering sustained growth, margin expansion, productivity improvement, and operational excellence.
  • Experience owning major P&L responsibility with accountability for revenue, EBITDA, budgets, and capital planning.
  • Deep expertise in specialty therapeutics, including chronic, rare, orphan, oncology, immunology, neurology, and other complex disease states.
  • Demonstrated success implementing Lean, Six Sigma, operational excellence, and process transformation initiatives.
  • Bachelor's degree required.
  • Black Belt or Master Black Belt certification preferred.
  • A master's degree is strongly preferred.
  • An MBA, MHA, R.Ph, PharmD, or other advanced healthcare/business degree is highly desirable.
Responsibilities
  • Develop and execute a multi-year specialty operations strategy aligned with growth objectives and specialty market expansion plans.
  • Lead all national specialty pharmacy operations, including dispensing, fulfillment, patient onboarding, pharmacy services, care coordination, admissions, reimbursement support, and operational centers of excellence.
  • Establish scalable operating models supporting growth across chronic, rare, orphan, oncology, immunology, neurology, and other specialty therapeutic areas.
  • Drive enterprise-wide operational consistency, service excellence, productivity, and patient outcomes across all sites and functions.
  • Serve as a key member of the Specialty and Enterprise Leadership Team, influencing organizational strategy and long-term investments.
  • Own operational performance across specialty pharmacy and buy-and-bill revenue cycle functions.
  • Lead enterprise strategies to maximize reimbursement, accelerate cash collections, reduce revenue leakage, improve clean claim rates, and optimize gross-to-net performance.
  • Oversee patient access, benefits investigation, prior authorization, financial assistance, copay support, claims management, collections, and reimbursement operations.
  • Partner with Finance and Commercial leaders to drive profitable growth, margin expansion, and operating leverage.
  • Manage a multi-hundred-million-dollar operating budget and deliver against growth and EBITDA targets.
  • Provide executive oversight across dispensing operations supporting chronic, rare, orphan, oncology, immunology, inflammatory, pulmonary, neurology, and gene/cell therapy-adjacent therapeutic categories.
  • Drive patient experience, adherence, persistence, and therapy outcomes.
  • Ensure operational readiness for emerging specialty medications, limited distribution drugs, manufacturer programs, and innovative care models.
  • Lead network optimization and operational scalability to support national expansion.
  • Serve as the executive sponsor for specialty operations digital transformation initiatives.
  • Champion enterprise automation strategies utilizing artificial intelligence, machine learning, predictive analytics, robotic process automation, workflow intelligence, and next-generation patient engagement technologies.
  • Modernize specialty pharmacy operating models to improve efficiency, quality, productivity, forecasting, patient engagement, and workforce effectiveness.
  • Create a data-driven operating environment with real-time operational dashboards, predictive performance metrics, and advanced analytics.
  • Establish a culture of operational excellence using Lean, Six Sigma, process engineering, and continuous improvement methodologies.
  • Lead enterprise initiatives focused on productivity improvement, cycle-time reduction, capacity optimization, quality enhancement, and cost reduction.
  • Implement standardized performance management frameworks and enterprise KPI governance.
  • Ensure rigorous accountability for operational, service, quality, compliance, and financial results.
  • Lead a large national organization consisting of vice presidents, regional leaders, directors, pharmacists, operations leaders, revenue cycle teams, reimbursement specialists, and support functions.
  • Build and develop a high-performance leadership team capable of supporting sustained growth and future expansion.
  • Attract, mentor, retain, and develop executive and emerging leadership talent.
  • Foster a culture centered on accountability, innovation, patient focus, collaboration, and execution excellence.
  • Partner with the EVP Specialty Sales & Solutions to support manufacturer, payer, provider, health system, and strategic growth initiatives.
  • Support diligence and integration activities related to acquisitions, strategic partnerships, and new business opportunities.
  • Translate market trends, competitive intelligence, and customer feedback into operational capabilities that create competitive advantage.
  • Represent Option Care Health with manufacturers, payers, health systems, accreditation organizations, and industry associations.
  • Ensure compliance with all federal, state, and regulatory requirements governing specialty pharmacy operations.
  • Maintain accreditation readiness and operational excellence related to URAC, ACHC, NABP, and other applicable standards.
  • Oversee patient safety, pharmacy quality programs, audit readiness, and enterprise risk management activities.
  • Ensure all operations adhere to legal, ethical, clinical, and regulatory standards.
Desired Qualifications
  • Executive leadership experience within a national specialty pharmacy organization, PBM specialty platform, integrated healthcare delivery organization, specialty infusion company, or large pharmaceutical services organization.
  • Experience supporting limited distribution drug networks, manufacturer services programs, and specialty commercialization efforts.
  • Experience integrating acquisitions and scaling enterprise operations during periods of rapid growth.
  • Master's degree, MBA, MHA, R.Ph, PharmD, or other advanced healthcare/business degree.

Option Care Health delivers infusion therapies at home and other alternate-site locations across the United States, supported by over 7,000 teammates including about 4,500 clinicians. Clinicians visit patients at home or approved sites to administer therapies, manage care, and coordinate with care teams under strong clinical leadership and national scale. It stands out as the largest independent infusion provider with nationwide reach and a robust clinical workforce, enabling scalable home and alternate-site infusion rather than hospital-only care. The goal is to elevate standards of care and reimagine the infusion care experience by expanding access, improving outcomes, and delivering compassionate, clinically driven service.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Norfolk, Virginia

Founded

1979

Get referred to Option Care Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $1.4 billion, with adjusted EBITDA up 12% to $117.5 million.
  • Management repurchased $150 million of shares in Q2 2026, nearly 5% outstanding.
  • Acute therapies grew high-single-digit organically, while chronic revenue stabilized after the CID reset.

What critics are saying

  • EEOC settled a June 2026 pregnancy discrimination lawsuit, exposing weak labor compliance controls.
  • OIG settlement cost $719,265 for referral-based compensation; regulators already see kickback risk.
  • CID headwinds still cut 2026 revenue about 600 basis points, threatening 2027 momentum.

What makes Option Care Health unique

  • Largest independent U.S. home and alternate-site infusion network spans 50 states and 5,000 clinicians.
  • Deep payer-integrated chronic and acute therapy platform keeps Option Care embedded in reimbursement workflows.
  • Massive scale supports purchasing leverage, specialty nursing capacity, and national referral coverage.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Time Off

Bonding Time Off

401(k) Retirement Plan

401(k) Company Match

Health Savings Account/Flexible Spending Account

Flexible Spending Accounts

Tuition Reimbursement

Family Support

Mental Health Support

Company Paid Life Insurance

Award/Recognition Programs

Company News

Yahoo Finance
Jul 29th, 2026
Option Care Health Q2 beats expectations with $1.4B revenue, narrows full-year guidance

Option Care Health reported second-quarter 2026 results that exceeded expectations. Revenue rose 7% sequentially to $1.4 billion, whilst adjusted EBITDA increased 12% to $117.5 million and adjusted EPS reached $0.45. Operating cash flow totalled $184 million. Acute therapies posted high-single-digit organic growth, while chronic revenue improved sequentially as the CID portfolio began to stabilise. However, CID-related pressure is expected to reduce 2026 revenue by roughly 600 basis points and gross profit by $55 million. The home and alternate-site infusion provider maintained its full-year revenue guidance at $5.675 billion to $5.775 billion. Adjusted EBITDA guidance was narrowed to $480 million to $495 million, and adjusted EPS guidance to $1.85 to $1.92. The company repurchased $150 million of shares, nearly 5% of shares outstanding.

Yahoo Finance
Jul 29th, 2026
Option Care Health reports $1.44B Q2 revenue, up 1.9%, and raises $150M share buyback

Option Care Health, the largest independent provider of home and alternate site infusion services in the US, reported second quarter 2026 results. Net revenue reached $1.44 billion, up 1.9% year-over-year. The company posted net income of $53.9 million, up 6.7%, with diluted earnings per share of $0.35, up 12.9%. Adjusted EBITDA grew 3.0% to $117.5 million. The company repurchased $150 million of outstanding shares during the quarter. For full year 2026, Option Care Health expects net revenue between $5.68 billion and $5.78 billion, with adjusted diluted earnings per share of $1.85 to $1.92. The company forecasts adjusted EBITDA of $480 million to $495 million and operating cash flow of at least $320 million.

Yahoo Finance
Jun 9th, 2026
Goldman Sachs initiates Option Care Health coverage with neutral rating, $22 price target

Option Care Health shares rose 3.5% after Goldman Sachs initiated coverage with a Neutral rating and a $22 price target, suggesting potential upside from the stock's recent price of $20.51. The move comes after the stock declined 33% over the previous six months. Whilst Goldman Sachs took a cautious stance, other firms including Deutsche Bank and UBS maintain Buy ratings on the stock. The company recently reported weak first-quarter 2026 results, with revenue of $1.35 billion missing forecasts despite a 1.3% year-on-year increase. Option Care Health also lowered its full-year revenue guidance to $5.73 billion, below analyst estimates. The stock is down 35.5% year-to-date and trading 43.2% below its 52-week high.

Associated Press
Jun 4th, 2026
Option Care Health appoints Robert Okunski as VP of investor relations

Option Care Health has appointed Robert Okunski as Vice President of Investor Relations, effective 26 May 2026. He will lead the company's investor relations strategy and serve as primary liaison with the investment community. Okunski brings over 20 years of investor relations experience across healthcare, technology and energy sectors. He joins from Enhabit Home Health & Hospice, where he served as Vice President of Investor Relations, and previously held senior positions at Velo3D, SunPower Corporation, Spansion and PeopleSoft. Option Care Health is the largest independent provider of home and alternate site infusion services in the US, employing over 8,000 staff including more than 5,000 clinicians across all 50 states.

Yahoo Finance
May 28th, 2026
Option Care Health posts weakest Q1 among home health stocks, shares drop 27%

Option Care Health, the largest independent provider of home infusion services in the US, reported Q1 revenues of $1.35 billion, up 1.3% year on year but missing analyst expectations by 3.3%. The company operates 177 locations across 43 states with over 4,500 clinicians. Chief executive John Rademacher acknowledged the "mixed performance" and expressed dissatisfaction with revenue growth momentum. Full-year guidance also fell short of analyst expectations. Across the senior health, home health and hospice sector, seven tracked companies reported a satisfactory Q1, with revenues beating consensus estimates by 0.9% on average. However, Option Care Health posted the weakest performance against analyst estimates despite raising full-year guidance. The stock has fallen 27.1% since reporting, currently trading at $21.59.